CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq: RARX) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $149.5 million.

Jefferies, BMO Capital Markets, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Baird acted as lead manager for the offering.

About Ra Pharmaceuticals, Inc.

Ra Pharma is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.